Login to Your Account



Pharma: Other News To Note


Wednesday, September 5, 2012
• Baxter International Inc., of Deerfield, Ill., said it submitted a biologics license application for approval of BAX 326, a recombinant Factor IX protein, for the treatment and prophylaxis of bleeding episodes for patients older than 12 with hemophilia B.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription